These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 7689782)
1. [Clinical study of allylestrenol (Perselin) on patients with prostatic hypertrophy]. Fukuoka H; Ishibashi Y; Shiba T; Tuchiya F; Sakanishi S Hinyokika Kiyo; 1993 Jul; 39(7):679-83. PubMed ID: 7689782 [TBL] [Abstract][Full Text] [Related]
2. [Clinical effects of allylestrenol on prostatic hypertrophy]. Kohri K; Kurita T; Iguchi M; Kataoka K Hinyokika Kiyo; 1986 Mar; 32(3):486-92. PubMed ID: 2425611 [TBL] [Abstract][Full Text] [Related]
3. [Clinical study of allylestrenol (Org AL-25) on patients with prostatic hypertrophy--transrectal ultrasonography and urodynamic examination]. Ohyama M; Tanifuji T; Haraguchi C; Fujii N; Higaki Y; Yoshida H; Imamura K Hinyokika Kiyo; 1986 Apr; 32(4):649-59. PubMed ID: 2426933 [TBL] [Abstract][Full Text] [Related]
4. [Clinical effects of allylestrenol on patients with benign prostatic hyperplasia (BPH) evaluated with criteria for treatment efficacy in BPH]. Noguchi K; Takeda M; Hosaka M; Kubota Y Hinyokika Kiyo; 2002 May; 48(5):269-73. PubMed ID: 12094708 [TBL] [Abstract][Full Text] [Related]
5. [Clinical effect of allylestrenol on benign prostatic hypertrophy]. Tajima A; Aso Y; Ushiyama T; Hata M; Kambayashi T; Ohmi Y; Masuda H; Nakahara M; Kitagawa M; Suzuki A Hinyokika Kiyo; 1986 Mar; 32(3):477-85. PubMed ID: 2425610 [TBL] [Abstract][Full Text] [Related]
6. [Clinical effects of allylestrenol on benign prostatic hypertrophy by double-blind method]. Shida K; Koyanagi T; Kawakura K; Nishida T; Kumamoto Y; Orikasa S; Sato S; Takeda M; Yamanaka H; Shimazaki J Hinyokika Kiyo; 1986 Apr; 32(4):625-48. PubMed ID: 2426932 [TBL] [Abstract][Full Text] [Related]
7. [A double-blind trial on the effect of bunazosin hydrochloride for the symptoms of benign prostatic hypertrophy]. Kumamoto Y; Tsukamoto T; Yachiku S; Kaneko S; Koyanagi T; Togashi M; Maru A; Tsuchida S; Nishizawa O; Orikasa S Hinyokika Kiyo; 1990 Oct; 36(10):1213-32. PubMed ID: 1702262 [TBL] [Abstract][Full Text] [Related]
8. [Long-term therapy with Robaveron tablet (KN-7) for urinary disturbance]. Tei K; Doi T; Sakai S; Fujimoto Y; Ban Y Hinyokika Kiyo; 1985 Apr; 31(4):731-8. PubMed ID: 2412422 [TBL] [Abstract][Full Text] [Related]
10. [Therapeutic effect of Robaveron tablet (KN-7) on urinary disturbance by benign prostatic hypertrophy]. Sonoda T; Endo H; Maru A; Sasaki K; Kuroda K; Takamura T; Inada F; Rokuzyo M; Ohori T; Kubo T Hinyokika Kiyo; 1985 Mar; 31(3):553-62. PubMed ID: 2411118 [TBL] [Abstract][Full Text] [Related]
11. [Effects of anti-androgens on sexual function. Double-blind comparative studies on allylestrenol and chlormadinone acetate. Part II: Self-assessment questionnaire method]. Kumamoto Y; Yamaguchi Y; Sato Y; Suzuki R; Tanda H; Kato S; Mori K; Matsumoto H; Maki A; Kadono M Hinyokika Kiyo; 1990 Feb; 36(2):227-44. PubMed ID: 1693038 [TBL] [Abstract][Full Text] [Related]
12. [Clinical effects of distigmine bromide (Ubretid), a cholinesterase inhibitor, on micturition disturbance by benign prostatic hypertrophy--comparative study of distigmine bromide and the combination of distigmine bromide and adrenergic blocker]. Katsumi T; Murayama K Hinyokika Kiyo; 1992 Sep; 38(9):1089-92. PubMed ID: 1384297 [TBL] [Abstract][Full Text] [Related]
13. [Fundamental and clinical study of the anti-prostatic effect of allylestrenol]. Yamanaka H; Kosaku N; Makino T; Shida K Hinyokika Kiyo; 1983 Sep; 29(9):1133-45. PubMed ID: 6203385 [TBL] [Abstract][Full Text] [Related]
14. [Clinical results and problems of anti-androgen therapy of benign prostatic hypertrophy]. Umeda K Hinyokika Kiyo; 1991 Nov; 37(11):1429-33. PubMed ID: 1722628 [TBL] [Abstract][Full Text] [Related]
15. [Clinical evaluation of cernilton in the treatment of the benign prostatic hypertrophy]. Horii A; Iwai S; Maekawa M; Tsujita M Hinyokika Kiyo; 1985 Apr; 31(4):739-46. PubMed ID: 2412423 [TBL] [Abstract][Full Text] [Related]
16. [Clinical evaluation of Cernilton in benign prostatic hypertrophy]. Hayashi J; Mitsui H; Yamakawa G; Suga A; Kai A; Shimabukuro T; Yanagi K; Fujisawa S; Takihara H; Kaneda Y Hinyokika Kiyo; 1986 Jan; 32(1):135-41. PubMed ID: 2421560 [TBL] [Abstract][Full Text] [Related]
17. [The effect of moxisylyte hydrochloride in the symptomatic treatment of benign prostatic hyperplasia]. Izumi H; Kudo S; Fuino A; Yokoyama E; Ishibashi A Hinyokika Kiyo; 1989 Mar; 35(3):541-9. PubMed ID: 2472054 [TBL] [Abstract][Full Text] [Related]
18. [Clinical studies on morphological changes in the prostate in patients with benign prostatic hypertrophy after antiandrogen therapy--by means of transrectal ultrasonotomography]. Suzuki K; Ichinose Y; Hashimoto K; Matsumoto K; Suzuki T; Imai K; Yamanaka H Hinyokika Kiyo; 1990 May; 36(5):557-60. PubMed ID: 1698012 [TBL] [Abstract][Full Text] [Related]
19. [Effect of KT-611 (Naftopidil) on the contraction of human prostatic tissue and its use in benign prostatic obstruction]. Yamanaka N; Yamaguchi O; Kameoka H; Fukaya Y; Yokota T; Shiraiwa Y; Yokoyama J; Kumakawa K; Itou K; Kuma Y Hinyokika Kiyo; 1991 Dec; 37(12):1759-72. PubMed ID: 1723843 [TBL] [Abstract][Full Text] [Related]
20. [Antiandrogen therapy of benign prostatic hyperplasia--review of the agents evaluation of the clinical results]. Kanimoto Y; Okada K Hinyokika Kiyo; 1991 Nov; 37(11):1423-8. PubMed ID: 1722627 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]